Lenvatinib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Candidate Biomarkers Associated with Survival: A Multicenter Study in Korea

Thyroid ◽  
2020 ◽  
Vol 30 (5) ◽  
pp. 732-738 ◽  
Author(s):  
Eyun Song ◽  
Mijin Kim ◽  
Eui Young Kim ◽  
Bo Hyun Kim ◽  
Dong Yeob Shin ◽  
...  
1995 ◽  
Vol 2 (2) ◽  
pp. 107327489500200
Author(s):  
Christopher L. Alexander ◽  
Roberto E. Izquierdo ◽  
James Figge ◽  
John Horton

Thyroid carcinoma, which comprises the majority of endocrine malignancies, has a substantial annual morbidity and mortality based on age and other predisposing factors. Diagnosis of a growing thyroid nodule can be difficult, but ultrasonography, radionuclide scanning, and fine needle aspiration allow the majority of nodules to be properly characterized. Treatment of differentiated thyroid carcinoma remains controversial. Surgical resection continues to be the most important modality with long survival if the tumor is resected early. Newer imaging techniques have improved the diagnosis of locally recurrent or metastatic disease. Radioactive iodine ablation is indicated for patients with “high-risk” tumors or advanced age. Few patients respond to cytotoxic chemotherapy. In the past decade, advances in the screening and diagnosis of medullary thyroid carcinoma have led to earlier detection with improvement in survival.


Thyroid ◽  
2016 ◽  
Vol 26 (11) ◽  
pp. 1623-1629 ◽  
Author(s):  
Rafael Selbach Scheffel ◽  
André B. Zanella ◽  
José Miguel Dora ◽  
Ana Luiza Maia

1997 ◽  
Vol 47 (6) ◽  
pp. 713-720 ◽  
Author(s):  
D. M. V. Pelikan ◽  
H. L. Lion ◽  
J. Hermans ◽  
B. M. Goslings

Sign in / Sign up

Export Citation Format

Share Document